Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Receivables (2024 - 2026)

Rani Therapeutics Holdings' Receivables history spans 3 years, with the latest figure at $2.0 million for Q1 2026.

  • On a quarterly basis, Receivables rose 240.33% to $2.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $2.0 million, a 240.33% increase, with the full-year FY2025 number at $2.0 million, up 410.5% from a year prior.
  • Receivables came in at $2.0 million for Q1 2026, roughly flat from $2.0 million in the prior quarter.
  • The five-year high for Receivables was $2.0 million in Q4 2025, with the low at $400000.0 in Q4 2024.
  • Historically, Receivables has averaged $1.3 million across 3 years, with a median of $1.3 million in 2025.
  • Biggest five-year swings in Receivables: surged 410.5% in 2025 and later skyrocketed 240.33% in 2026.
  • Year by year, Receivables stood at $400000.0 in 2024, then skyrocketed by 410.5% to $2.0 million in 2025, then changed by 0.0% to $2.0 million in 2026.
  • Business Quant data shows Receivables for RANI at $2.0 million in Q1 2026, $2.0 million in Q4 2025, and $600000.0 in Q1 2025.